Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tofersen + 99mTc-MAG3-BIIB067
- Development stage
- Unknown
- Lead developer
- Biogen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal, Intravenous
01
Overview
**Tofersen + 99mTc-MAG3-BIIB067** is a combination of an antisense oligonucleotide drug (tofersen), used for the treatment of amyotrophic lateral sclerosis (ALS) with confirmed SOD1 mutation, and a technetium-99m–labeled mercaptoacetyltriglycine (99mTc-MAG3), a radiopharmaceutical. This specific combination is utilized for imaging and in vivo distribution studies to assess the CNS biodistribution of tofersen, with 99mTc-MAG3 serving as a radiotracer. Tofersen acts by binding SOD1 mRNA, reducing SOD1 protein synthesis and thereby targeting the underlying pathogenic mechanism in SOD1-ALS. 99mTc-MAG3 is a renal imaging agent commonly used for nuclear medicine assessments, here chemically conjugated for the specific purpose of tracing tofersen pharmacokinetics via SPECT/CT imaging.
- Other names
- tofersen + 99mTc-MAG3-BIIB067
02
Targets
SOD (Manganese Superoxide Dismutase)
Beyond the preview
Go deeper on tofersen + 99mTc-MAG3-BIIB067.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tofersen + 99mTc-MAG3-BIIB067.